Beacon Biosignals’ Post

Exciting News from Canary Speech! Announcing the expansion of our vocal biomarker offerings in the neurological space, now covering mild cognitive impairment (MCI), Alzheimer’s Disease, and Parkinson’s Disease. Learn more about this groundbreaking development in our latest article: https://lnkd.in/eUZfGrx9 Early diagnosis is crucial for cognitive conditions like MCI and Alzheimer’s. Yet, many cases go undetected. Our innovative technology aims to change that by providing accurate and non-invasive screening methods. Discover how Canary Speech is leading the way in proactive neurological care. Our vocal biomarker solution offers a lifeline, enabling early intervention to improve patients' quality of life. Join us in revolutionizing neurological care! #CanarySpeech #HealthAI #EarlyDiagnosis

Inspiring advancements in AI for the diagnosis of dementia 💫

A new tool to track the neurons and molecules activated in the brain by psychedelic drugs could help scientists unlock the benefits of psychedelic treatments for patients with brain disorders: https://lnkd.in/eW_uQBAb #psychedelics #psilocybin #DMT

Starting a New Chapter with Beacon Biosignals – embarking on a new journey as Vice President of Translational Medicine! I'm thrilled to be joining Jacob Donoghue, MD PhD, Jarrett Revels, David Matthews, PhD and the brilliant team at Beacon, and leveraging my experience in neurophysiology and biomarker evaluation to explore the fascinating connection between brain activity, cognition, research & drug development, for generating meaningful and impactful solutions to millions of people in need. Ever since my PhD, I have been passionate about neural network activity and its role in various brain pathology and pathophysiology. The study of brain waves and oscillations has revealed their crucial role in brain function, both in normal conditions and as underlying factors in various pathologies. Yet, a lot more needs to be done to characterize the highly nuanced, context-dependent inter-play of these factors in disease onset and progression. At Beacon, I'm driven by the potential of advanced neurotechnologies to unlock the complexities of brain activity, particularly in psychiatric and neurologic diseases. We have the tools to record vast amounts of data, but extracting meaningful insights remains a challenge. Beacon's remarkable partnerships with clinical centers, pharmaceutical companies, and its cutting-edge AI/ML analysis offer immense potential to identify unique features of brain activity and revolutionize our understanding of disease heterogeneity. The applications of Beacon's platform are vast, spanning rare and common neurodegenerative and neuropsychiatric disorders. From optimizing clinical trial design to patient stratification and outcome assessments, the opportunities to transform patient care are truly limitless. I look forward to bringing together my collective knowledge and experience in neuroscience research, strategic partnerships, and alliances to my new role at Beacon. Importantly, given the critical unmet need of more novel biomarkers in neurodegenerative and neuropsychiatric drug development and regulatory science, I am excited to leverage knowledge from my recent experience working with the industry and regulatory agencies (#FDA, #EMA) in Alzheimer’s disease to advance our understanding and identification of evidentiary considerations for the development and evaluation of biomarkers, towards our work at Beacon. Alexander Chan Corey Puryear Megan Means, MSHR Jay Pathmanathan Dan Florey Gregory Klein Lars Lau Raket Antoine Leuzy Michael Gold Robert Alexander Heather M. Snyder Christopher Weber Rebecca Edelmayer R.Matthew Hutchison Jessica Collins Rik Ossenkoppele Oskar Hansson Ara Khachaturian Lenka Uldrijanova Hartmuth Kolb Viswanath Devanarayan Jamie Maguire #Neurology #Psychiatry #PrecisionMedicine #BrainHealth #BeaconBiosignals #AI #ML #neuropsychiatricdisorders #neurodegenerativediseases #regulatoryscience #digitalhealth #Sleep #EEG #biomarkers #drugdevelopment

First Human Mini-Brain with Functional Blood-Brain Barrier Unveiled This development could accelerate #drugdiscovery and therapeutic interventions for various brain disorders: https://lnkd.in/gTwhV7xy

Over 6.7 million seniors in the US battle Alzheimer's, facing not just memory loss but also anxiety and agitation, affecting nearly all patients. Shockingly, there's only one FDA-approved drug for agitation in Alzheimer's, leaving a huge gap in treatment options. That's where CBD steps in. Preclinical studies highlight CBD's ability to alleviate stress and anxiety, while also exhibiting neuroprotective properties by targeting tau hyperphosphorylation, a key feature of AD pathology. This research underscores CBD's promise as a potential therapy for anxiety and agitation in AD, paving the way for future investigations into its efficacy and safety. https://lnkd.in/g_6YVJqg

Researchers from the University of Pittsburgh School of Medicine revealed a new discovery about Alzheimer’s disease. Instead of the commonly studied amyloid and tau proteins, they found that the challenging symptoms like irritability, agitation, and depression stem more from brain inflammation. They studied 109 elderly individuals and saw a strong link between this neuroinflammation and these difficult symptoms. This points to fresh ways to treat Alzheimer’s by focusing on reducing brain inflammation, which could help with both the cognitive and emotional struggles experienced by patients. This breakthrough supports the idea that brain inflammation plays a bigger role in the early stages of Alzheimer’s than previously thought. By highlighting this link between neuroinflammation and the troublesome symptoms, especially rapid mood swings, the study opens doors for new treatments. This research direction could lead to clinical trials targeting brain inflammation, potentially making treatments more effective and improving the lives of both patients and caregivers. #AlzheimersResearch #Neuroinflammation #BrainHealth #TreatmentDevelopment #UniversityofPittsburgh https://lnkd.in/g_MAbVWX

To combat Alzheimer's disease, a potential treatment has emerged from Cognito Therapeutics, Inc. Their experimental headset, Spectris, designed to use light and sound, promises a drug-free approach to tackling cognitive decline in Alzheimer's patients. 👓🎧 The headset delivers flashing lights and sounds to stimulate gamma waves in the brain, offering a new approach to combating the effects of Alzheimer's. 🧠💡Gamma waves, associated with critical thinking and memory, are often diminished in Alzheimer's patients. Spectris aims to address this by stimulating gamma wave activity through synchronized light and sound, fostering stronger connections among brain networks and potentially slowing cognitive decline. 🔬📊Results from a Phase II trial demonstrate Spectris's safety and efficacy in slowing functional and cognitive decline in Alzheimer's patients. With a Phase III trial on the horizon, Cognito Therapeutics hopes to further validate the potential of Spectris as a standalone therapy or complement to existing treatments. Read more below. #SpectrisSolutions #AlzheimersInnovation #LightAndSoundTherapy #Alzheimers #Brain #STEM #Discovery #Research #Innovation #Science #Treatment

20-year study maps Alzheimer's progression, offering hope for early detection NEJM Group Researchers tracked changes in brains, including protein levels & brain shrinkage #alzheimers #EndAlzheimers #diagnostics #MedicalDiagnostics

【Exploring the Potential of Cilostazol in Mild Cognitive Impairment: Insights from the COMCID Study in Japan】 In 2015, a research project led by well-established Japanese scientists, including Masafumi Ihara and Satoshi Saito at NCVC, initiated the COMCID study, the first in Japan focusing on Mild Cognitive Impairment (MCI). This comprehensive, multicenter trial investigated the safety and efficacy of cilostazol in patients with MCI. While the study confirmed the drug's safety, it did not establish its effectiveness in preventing the progression of MCI to dementia. However, an interesting biochemical effect was observed: patients treated with cilostazol showed increased levels of the albumin and β-amyloid complex in their blood. This suggests cilostazol might help clear β-amyloid, associated with dementia, from the brain. Based on these findings and previous research indicating cilostazol's potential in improving cognitive functions, future studies aim to identify specific individuals who could benefit from the drug, focusing on its possible anti-dementia effects. The results were reported in the journal JAMA Network Open on December 4, 2023. https://lnkd.in/gi56J7dP